Solana Co Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Solana Co (formerly Helius Medical Technologies) performed this year. My goal is to explain their latest filing in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Solana Co is undergoing a major identity shift. They are moving away from their roots as a medical technology company—specifically the "PoNS" device—to focus on the cryptocurrency space. They are now building a "token treasury," staking assets, and exploring the Solana blockchain. Their new business model focuses on managing digital assets to earn interest and grow their value, rather than selling medical hardware.

2. Financial performance: The "Survival" Phase

The company is currently operating at a loss. For the year ending December 31, 2025, they reported a $14.2 million loss, compared to $11.8 million the previous year. They are spending about $1.1 million per month to fund their new crypto strategy. Because their medical business revenue dropped 40%, they rely on selling stock to fund operations. They raised $18.5 million by issuing new shares and "warrants," which are contracts that let buyers purchase shares later at $2.50 each.

3. Major wins and challenges

• Wins: They successfully raised $18.5 million through private sales and stock offerings. This left them with $4.2 million in cash at the end of 2025, providing roughly four months of operating runway.
• Challenges: In 2025, the company corrected a $2.1 million overvaluation of their digital assets. This adjustment highlights the complexities involved in their current accounting for crypto holdings.

4. Financial health: The "Dilution" Trap

This is a critical factor for investors. Because the company issues new shares to raise cash, your ownership stake is diluted. As of March 31, 2026, they had 55 million shares outstanding—a 28% increase from the start of 2025. Every time they issue new shares to pay bills, the value of existing shares is impacted.

5. Key risks to watch

• Dilution: The company has authorization to sell up to $50 million in additional stock. This potential for future share issuance can create downward pressure on the stock price.
• The "Pivot" Risk: They are transitioning from a regulated medical business to the volatile, unregulated crypto market. This is a significant change in strategy with no long-term track record to rely on.
• Customer Concentration: Their medical revenue is highly dependent on one distributor, which provided 65% of their total income in 2025.

6. Future outlook

The company plans to acquire $25 million in additional digital assets by the end of 2026. They are heavily committed to the Solana blockchain. Investors should expect continued losses and potential stock sales until the company can demonstrate that its crypto strategy generates more value than it consumes.

Final Thought for Investors: When considering this company, ask yourself if you are comfortable with a business that is essentially a startup in the crypto space. Because they are burning cash and relying on share dilution to stay alive, the primary question is whether their digital asset strategy will eventually generate enough profit to stop the need for constant fundraising. If you are looking for stability, this transition phase carries significant risk.